Neuberg Diagnostics, Chennai, has introduced Mispa i60, a simple blood-based test designed to detect early signs of Alzheimer’s disease, offering a non-invasive and cost-effective screening solution.

The test utilizes key biomarkers such as phosphorylated tau (p-tau) and amyloid proteins, which are closely linked to Alzheimer’s pathology. By identifying these markers, the test enables detection of disease-related changes well before the onset of noticeable cognitive decline. While it supports early screening, the test is intended to complement clinical evaluation and does not replace neuroimaging or cerebrospinal fluid (CSF) testing.

Commenting on the development, Dr. Asma Bibi, Chief of Laboratory at Neuberg Diagnostics, noted that Alzheimer’s disease often presents with symptoms similar to other forms of dementia, making accurate diagnosis challenging. She emphasized that biomarker-based testing can help differentiate Alzheimer’s from other dementia syndromes, ensuring patients receive appropriate and timely treatment.

Initial data from patients tested at Neuberg’s OMR centre showed that 45 Percent had an elevated tau-to-amyloid ratio, indicating potential Alzheimer’s pathology. These findings were corroborated through neurologist assessments and clinical evaluations, demonstrating strong alignment with conventional diagnostic approaches.

The blood-based testing approach offers several advantages over traditional methods. It reduces reliance on invasive CSF procedures and expensive brain imaging, while providing faster results and improved patient comfort. Its affordability and accessibility make it particularly suitable for broader adoption, including in regional and resource-limited settings.

With Alzheimer’s disease continuing to impact a growing global population, early detection remains critical for effective disease management. Innovations such as Mispa i60 are expected to enhance early screening capabilities, enabling timely intervention and improving patient outcomes across both urban and regional healthcare settings, including Tamil Nadu.